Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2110183 Gelatin · 1 trial · 1 indication
PK parameters include: area under the plasma concentration-time curve from time zero to infinity (AUC \[0-infinity\]), area under the plasma concentration time curve from time zero to last time of quantifiable concentration (AUC \[0-t\]), maximum observed plasma concentration (Cmax), and time to Cmax (tmax).
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC |
| Sequence 2 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB |
| Sequence 3 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC |
| Sequence 4 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA |
| Sequence 5 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB |
| Sequence 6 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA |
| Name | Type | Description |
|---|---|---|
| GSK2110183 Gelatin Capsule | DRUG | White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration |
| GSK2110183 IR Tablet | DRUG | White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration |
Inclusion Criteria: * Provided signed written informed consent * Healthy Male or female between 18 and 40 years of age inclusive, at the time the informed consent is obtained. * Body weight \>=50 kilograms (kg) and body mass index (BMI) of \>=18 and \<= 32 kg/meter square (m\^2). * A female subject...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
GSK2110183 Gelatin is an investigational small molecule being developed by GSK plc for the treatment of cancer. It is currently in Phase 1 clinical development. The drug is being studied in a completed clinical trial that evaluated its bioavailability and food effects.
GSK2110183 Gelatin is being studied for use in cancer. It is an investigational oncology drug in Phase 1 clinical development. The completed clinical trial enrolled patients with cancer to assess the drug's bioavailability and the effect of food on its absorption.
GSK2110183 Gelatin is developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The drug is an investigational small molecule being studied for the treatment of cancer.
GSK2110183 Gelatin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug remains under investigation for cancer.
GSK2110183 Gelatin has one completed clinical trial, NCT02040480, titled "Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib." This Phase 1 study enrolled 18 participants in Australia and evaluated the drug in cancer patients.